Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats.
Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats.
复制标题
等效抗高血压药物对自发性高血压大鼠的脉动血流动力学和心脏肥大的消退有不同的影响。
DOI:
10.1161/01.cir.94.11.2923
复制
发表时间:
1996
期刊:
影响因子:
37.8
通讯作者:
Pfeffer,JM
中科院分区:
文献类型:
--
作者:
Mitchell,GF;Pfeffer,MA;Finn,PV;Pfeffer,JM
BackgroundConverting enzyme inhibitors are more effective than arteriolar vasodilators at regressing left ventricular hypertrophy in spontaneously hypertensive rats (SHR), possibly because of nonhemodynamic factors. However, the pulsatile component of hemodynamic load has not been evaluated in this model.Methods and ResultsWe measured pulsatile hemodynamics in 18-month-old male SHR after 6 months of therapy with either zofenopril (Z), hydralazine (H), or water (W). Hydralazine and zofenopril reduced mean arterial pressure comparably (W, 106±23 versus H, 81±12 versus Z, 84±18 mm Hg,P=.002) yet had a differential effect on the ratio of left ventricular weight to body weight (W, 3.9±0.5 versus H, 3.3±0.4 versus Z, 2.4±0.2 g/kg,P<.005). Hydralazine-treated SHR had increased characteristic impedance (P=.0011) and a persistently low ratio of the reflected-wave transit time to left ventricular ejection time (P<.001), which contributed to early and late systolic loading, respectively, of the left ventricle. Consequently, only zofenopril-treated SHR had a significant reduction in left ventricular systolic force-time integral (P=.02), a measure of total ventricular load. There were no differences in systolic stress-time integral, suggesting that mass was appropriate to load when all elements of steady-flow and pulsatile load were considered.ConclusionsA blunted reduction in total left ventricular load, due to increased pulsatile load in SHR treated with hydralazine, provided a hemodynamic basis for the differential regression of hypertrophy in this model of genetic hypertension.